The mast cell activator compound 48/80 is safe and effective when used as an adjuvant for intradermal immunization with Bacillus anthracis protective antigen.
Journal Article (Journal Article)
We evaluated the safety and efficacy of the mast cell activator compound 48/80 (C48/80) when used as an adjuvant delivered intradermally (ID) with recombinant anthrax protective antigen (rPA) in comparison with two well-known adjuvants. Mice were vaccinated in the ear pinnae with rPA or rPA+C48/80, CpG oligodeoxynucleotides (CpG), or cholera toxin (CT). All adjuvants induced similar increases in serum anti-rPA IgG and lethal toxin neutralizing antibodies. C48/80 induced a balanced cytokine production (Th1/Th2/Th17) by antigen-restimulated splenocytes, minimal injection site inflammation, and no antigen-specific IgE. Histological analysis demonstrated that vaccination with C48/80 reduced the number of resident mast cells and induced an injection site neutrophil influx within 24h. Our data demonstrate that C48/80 is a safe and effective adjuvant, when used by the intradermal route, to induce protective antibody and balanced Th1/Th2/Th17 responses.
Full Text
Duke Authors
Cited Authors
- McGowen, AL; Hale, LP; Shelburne, CP; Abraham, SN; Staats, HF
Published Date
- June 2, 2009
Published In
Volume / Issue
- 27 / 27
Start / End Page
- 3544 - 3552
PubMed ID
- 19464533
Pubmed Central ID
- PMC2743390
International Standard Serial Number (ISSN)
- 0264-410X
Digital Object Identifier (DOI)
- 10.1016/j.vaccine.2009.03.069
Language
- eng
Conference Location
- Netherlands